

Zoe Moodie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1773481/publications.pdf>

Version: 2024-02-01

54
papers

4,905
citations

236612

25
h-index

205818

48
g-index

58
all docs

58
docs citations

58
times ranked

6369
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a caseâ€“cohort analysis. <i>Lancet</i> , The, 2008, 372, 1894-1905. | 6.3 | 670 |
| 2 | Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy. <i>New England Journal of Medicine</i> , 2018, 379, 327-340. | 13.9 | 557 |
| 3 | mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. <i>Science</i> , 2021, 372, 1413-1418. | 6.0 | 468 |
| 4 | Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 507-515. | 4.6 | 330 |
| 5 | Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. <i>Cell Reports Medicine</i> , 2021, 2, 100354. | 3.3 | 316 |
| 6 | Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIVâ€“1 Candidate Vaccine Delivered by a Replicationâ€“Defective Recombinant Adenovirus Vector. <i>Journal of Infectious Diseases</i> , 2006, 194, 1638-1649. | 1.9 | 283 |
| 7 | Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. <i>Journal of Immunological Methods</i> , 2007, 323, 39-54. | 0.6 | 223 |
| 8 | A DNA Vaccine for Ebola Virus Is Safe and Immunogenic in a Phase I Clinical Trial. <i>Vaccine Journal</i> , 2006, 13, 1267-1277. | 3.2 | 221 |
| 9 | Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIVâ€“1 DNA Candidate Vaccine. <i>Journal of Infectious Diseases</i> , 2006, 194, 1650-1660. | 1.9 | 200 |
| 10 | Overcoming Immunity to a Viral Vaccine by DNA Priming before Vector Boosting. <i>Journal of Virology</i> , 2003, 77, 799-803. | 1.5 | 197 |
| 11 | Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120â€“MF59 in Adults. <i>New England Journal of Medicine</i> , 2021, 384, 1089-1100. | 13.9 | 144 |
| 12 | A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204). <i>PLoS ONE</i> , 2011, 6, e21225. | 1.1 | 131 |
| 13 | Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 388-396. | 4.6 | 108 |
| 14 | Immunogenicity of Multiple Gene and Clade Human Immunodeficiency Virus Type 1 DNA Vaccines. <i>Journal of Virology</i> , 2003, 77, 12764-12772. | 1.5 | 90 |
| 15 | Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. <i>Lancet HIV</i> , the, 2018, 5, e366-e378. | 2.1 | 86 |
| 16 | Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America. <i>Journal of Infectious Diseases</i> , 2018, 217, 742-753. | 1.9 | 80 |
| 17 | Optimizing Viable Leukocyte Sampling from the Female Genital Tract for Clinical Trials: An International Multi-Site Study. <i>PLoS ONE</i> , 2014, 9, e85675. | 1.1 | 73 |
| 18 | Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials. <i>Journal of Immunological Methods</i> , 2006, 315, 121-132. | 0.6 | 63 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Virus-Specific CD8 ⁺ T-Cell Responses Better Define HIV Disease Progression than HLA Genotype. <i>Journal of Virology</i> , 2010, 84, 4461-4468. | 1.5 | 50 |
| 20 | Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054). <i>PLoS ONE</i> , 2010, 5, e13579. | 1.1 | 47 |
| 21 | Pooled-Peptide Epitope Mapping Strategies Are Efficient and Highly Sensitive: An Evaluation of Methods for Identifying Human T Cell Epitope Specificities in Large-Scale HIV Vaccine Efficacy Trials. <i>PLoS ONE</i> , 2016, 11, e0147812. | 1.1 | 42 |
| 22 | Differences in HIV-Specific T Cell Responses between HIV-Exposed and -Unexposed HIV-Seronegative Individuals. <i>Journal of Virology</i> , 2011, 85, 3507-3516. | 1.5 | 38 |
| 23 | Hormonal contraception alters vaginal microbiota and cytokines in South African adolescents in a randomized trial. <i>Nature Communications</i> , 2020, 11, 5578. | 5.8 | 30 |
| 24 | Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men. <i>PLoS ONE</i> , 2015, 10, e0137666. | 1.1 | 30 |
| 25 | Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083. <i>Journal of Infectious Diseases</i> , 2016, 213, 541-550. | 1.9 | 28 |
| 26 | Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. <i>PLoS Medicine</i> , 2020, 17, e1003038. | 3.9 | 27 |
| 27 | Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells. <i>Frontiers in Immunology</i> , 2019, 10, 2741. | 2.2 | 25 |
| 28 | Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial Reveals an Association of Nonspecific Interferon- γ Secretion with Increased HIV-1 Infection Risk: A Cohort-Based Modeling Study. <i>PLoS ONE</i> , 2014, 9, e108631. | 1.1 | 23 |
| 29 | Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials. <i>PLoS ONE</i> , 2015, 10, e0136626. | 1.1 | 23 |
| 30 | Quantitative and Qualitative Differences in the T Cell Response to HIV in Uninfected Ugandans Exposed or Unexposed to HIV-Infected Partners. <i>Journal of Virology</i> , 2013, 87, 9053-9063. | 1.5 | 19 |
| 31 | HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens. <i>Scientific Reports</i> , 2020, 10, 2093. | 1.6 | 17 |
| 32 | Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans. <i>PLoS ONE</i> , 2020, 15, e0226803. | 1.1 | 16 |
| 33 | Assessment of the long-term efficacy of a dengue vaccine against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatus. <i>Vaccine</i> , 2020, 38, 3531-3536. | 1.7 | 12 |
| 34 | Immunization with a self-assembling nanoparticle vaccine displaying EBV gH/gL protects humanized mice against lethal viral challenge. <i>Cell Reports Medicine</i> , 2022, 3, 100658. | 3.3 | 12 |
| 35 | Comparing and combining data across multiple sources via integration of paired sample data to correct for measurement error. <i>Statistics in Medicine</i> , 2012, 31, 3748-3759. | 0.8 | 11 |
| 36 | Analysis of the HIV Vaccine Trials Network 702 Phase 2b HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk. <i>Journal of Infectious Diseases</i> , 2022, 226, 246-257. | 1.9 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Chemoprophylaxis Vaccination: Phase I Study to Explore Stage-specific Immunity to Plasmodium falciparum in US Adults. <i>Clinical Infectious Diseases</i> , 2020, 71, 1481-1490. | 2.9 | 9 |
| 38 | Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America. <i>PLoS ONE</i> , 2020, 15, e0234236. | 1.1 | 9 |
| 39 | Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 101, 164-179. | 0.6 | 9 |
| 40 | Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials. <i>PLoS Medicine</i> , 2020, 17, e1003117. | 3.9 | 8 |
| 41 | New clinical trial designs for HIV vaccine evaluation. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 437-442. | 1.5 | 6 |
| 42 | Comparison of Sexual Behavior and HIV Risk between Two HIV-1 Serodiscordant Couple Cohorts: The CHAVI 002 Study. <i>PLoS ONE</i> , 2012, 7, e37727. | 1.1 | 5 |
| 43 | Periods of high dengue transmission defined by rainfall do not impact efficacy of dengue vaccine in regions of endemic disease. <i>PLoS ONE</i> , 2018, 13, e0207878. | 1.1 | 5 |
| 44 | Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy. <i>PLoS ONE</i> , 2016, 11, e0152952. | 1.1 | 4 |
| 45 | Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection. <i>MSphere</i> , 2020, 5, . | 1.3 | 3 |
| 46 | Associations of human leukocyte antigen with neutralizing antibody titers in a tetravalent dengue vaccine phase 2 efficacy trial in Thailand. <i>Human Immunology</i> , 2022, 83, 53-60. | 1.2 | 3 |
| 47 | Analysis of Neutralizing Antibodies as a Correlate of Instantaneous Risk of Hospitalized Dengue in Placebo Recipients of Dengue Vaccine Efficacy Trials. <i>Journal of Infectious Diseases</i> , 2022, 225, 332-340. | 1.9 | 1 |
| 48 | Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials. <i>PLoS Pathogens</i> , 2021, 17, e1010016. | 2.1 | 1 |
| 49 | Vaccine Enhancement Confirmed among Men in HVTN 503-S, Final Results from a Recall Study of Phambili Participants. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A32-A33. | 0.5 | 0 |
| 50 | Incident Herpes Simplex Virus Type 2 Associated with HIV Infection in Phambili. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A29-A30. | 0.5 | 0 |
| 51 | Title is missing!. , 2020, 15, e0234236. | | 0 |
| 52 | Title is missing!. , 2020, 15, e0234236. | | 0 |
| 53 | Title is missing!. , 2020, 15, e0234236. | | 0 |
| 54 | Title is missing!. , 2020, 15, e0234236. | | 0 |